Document is current

Article History

Received: 28 January 2025

Accepted: 23 September 2025

First Online: 7 November 2025

Declarations

:

: A.G., N.P.R., S.B., and B.S.M. are employees of AbbVie. Employees of AbbVie may hold equity. S.K. is an employee of PIVINA and C.V. is the managing director of PIVINA Consulting Inc., a company that has served as a consultant to AbbVie and has received research funding from AbbVie. G.W., L.B. and G.R. are employees of OPEN Health, which served as a consultant to AbbVie and has received research funding from AbbVie. C.O. has received research funding from AbbVie, Roche, AstraZeneca, Janssen, Beigene, and Merck and has served as a consultant to AbbVie, Astrazeneca, Beigene, Janssen, Roche, and Merck. V.B. has received research funding from CIHR, CancerCare Manitoba, University of Manitoba, AstraZeneca, and Eli Lilly. V.B. has contracts with Beigene, AbbVie, and Janssen related to the CLL Unit, and has served as a consultant to AbbVie, Janssen, AstraZeneca, Merck, Eli Lilly, and Beigene.

: Not applicable.

: Not applicable.

: Not applicable.

: Data reported in this manuscript are available within the article and its supplementary materials. Additional data may be requested by contacting AbbVie.

: Code may be requested by contacting AbbVie.

: All named authors meet the International Committee of Medical Journal Editors criteria for authorship for this article, take responsibility for the integrity of the work as a whole, and have given final approval to the version to be published. AbbVie, OPEN Health, and PIVINA Consulting Inc. participated in the design, study conduct, analysis and interpretation of data, as well as the writing, review, and approval of the manuscript. C.O. and V.B. were involved in study conception and design, data interpretation and revision of the manuscript.